TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
TEVA$42.40-1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
(U.S. dollars in millions)
| Three months ended · Nine months ended | ||||
|---|---|---|---|---|
| September 30, | September 30, | |||
| 2026 | 2025 | 2026 | 2025 | |
| Operating activities: | ||||
| Net income (loss) | $234 | $434 | $27 | $937 |
| Adjustments to reconcile net income (loss) to net cash provided by operations: | ||||
| Depreciation and amortization | 245 | 249 | 725 | 742 |
| Impairment of long-lived assets and assets held for sale | 228 | 79 | 350 | 255 |
| Acquired in-process research and development* | 23 | 17 | 785 | 52 |
| Net change in operating assets and liabilities | (682) | (578) | (1,523) | (1,647) |
| Deferred income taxes – net and uncertain tax positions | 53 | 107 | 56 | (76) |
| Stock-based compensation | 38 | 34 | 121 | 106 |
| Loss on extinguishment of debt | 224 | — | 224 | — |
| Other items | (53) | 27 | (65) | 122 |
| Net loss (gain) from sale of business and long-lived assets | (69) | — | (89) | — |
| Net cash provided by (used in) operating activities | 241 | 369 | 612 | 491 |
| Investing activities: | ||||
| Beneficial interest collected in exchange for securitized trade receivables | 327 | 274 | 992 | 932 |
| Purchases of property, plant and equipment and intangible assets | (120) | (136) | (393) | (359) |
| Proceeds from sale of businesses and long-lived assets, net | 47 | 8 | 93 | 34 |
| Purchases of in-process research and development* | (46) | (12) | (747) | (41) |
| Other investing activities | 2 | 1 | 3 | 6 |
| Net cash provided by (used in) investing activities | 210 | 135 | (52) | 572 |
| Financing activities: | ||||
| Repayment of senior notes and loans and other long-term liabilities | (4,883) | (444) | (4,906) | (4,112) |
| Proceeds from senior notes, net of issuance costs | 4,845 | (7) | 4,845 | 2,298 |
| Purchase of shares from redeemable and non-redeemable non-controlling interests | — | — | — | (38) |
| Dividends paid to redeemable and non-redeemable non-controlling interests | — | — | — | (340) |
| Other financing activities | 43 | (2) | 78 | 1 |
| Net cash provided by (used in) financing activities | 6 | (453) | 18 | (2,191) |
| Effect of exchange rate changes on cash and cash equivalents | (27) | (9) | (49) | 31 |
| Net change in cash and cash equivalents | 430 | 42 | 529 | (1,097) |
| Balance of cash, cash equivalents at beginning of period | 3,655 | 2,161 | 3,556 | 3,300 |
| Balance of cash, cash equivalents at end of period | 4,085 | 2,203 | 4,085 | 2,203 |
| Non-cash financing and investing activities: | ||||
| Beneficial interest obtained in exchange for securitized accounts receivables | $253 | 296 | $859 | 937 |
| Receivable for sale of long-lived assets | 90 | — | 90 | — |
| Net change in operating assets and liabilities: | ||||
| Other assets | $(233) | $(289) | $(835) | $(1,033) |
| Trade payables, accrued expenses, employee-related obligations and other liabilities | (109) | (309) | (209) | (300) |
| Trade receivables net of sales reserves and allowances | (311) | (145) | (298) | (298) |
| Inventories | (29) | 165 | (181) | (16) |
| $(682) | $(578) | $(1,523) | $(1,647) | |
*In the first nine months of 2026, mainly related to the acquisition of Emalex and its primary asset ecopipam (EBS-101). See ‘Emalex Biosciences’ included in note 2.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.